Costs for the development and production of a new vaccine are great. Imvamune, a prospective, still unlicensed new vaccine has recently been acquired for the national stockpile. The cost for this vaccine for just 10 million people was more than $500 million. It may be safer for those with eczema or immune deficiency diseases, but, so far, it has been given to fewer than 8,000 people. It requires syringe and needle injection of two doses, 30 days apart. Adequate protection is not achieved until 45 days after the first dose. I cannot envisage how this vaccine might be used. No other candidate vaccines are on the horizon.